GB1559456A - Process for the production of 9-d-arabinofuranosyl-adenine5-phosphate - Google Patents
Process for the production of 9-d-arabinofuranosyl-adenine5-phosphate Download PDFInfo
- Publication number
- GB1559456A GB1559456A GB4564777A GB4564777A GB1559456A GB 1559456 A GB1559456 A GB 1559456A GB 4564777 A GB4564777 A GB 4564777A GB 4564777 A GB4564777 A GB 4564777A GB 1559456 A GB1559456 A GB 1559456A
- Authority
- GB
- United Kingdom
- Prior art keywords
- adenine
- arabinofuranosyl
- phosphate
- aqueous
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The 9-( beta -D-arabinofuranosyl)adenine 5'-phosphate is prepared from a mixture obtained by reaction of 9-( beta -D-arabinofuranosyl)adenine with a phosphorylating agent, in a trialkyl phosphate as solvent. The mixture is then subjected to an aqueous hydrolysis, the pH of the hydrolysis mixture is adjusted to a value sufficiently high to bring about separation into aqueous and nonaqueous liquid phases; the trialkyl phosphate, which is the solvent, is removed and then the product is precipitated so as to separate it from the residual aqueous mixture and it is isolated.
Description
(54) PROCESS FOR THE PRODUCTION OF 9-(ss-D-ARABINOFURANOSYL)- ADENINE, 5'-PHOSPHATE
(71) We, PARKE, DAVIS & COMPANY, a corporation organised under the laws of the State of Michigan, one of the United States of America, of Joseph Campau at the River,
Detroit, Michigan 48207, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:
This invention relates to a process for the production of the ester product, 9-(ss-D- arabinofuranosyl)-adenine, 5'-phosphate, by phosphorylation of 9-(ss-D- arabinofuranosyl) adenine and hydrolysis of the phoshphorylated product. More particularly, the present invention relates to such a process in which the desired ester product is obtained in crystalline form directly from the reaction mixture.
United States Patent Specification No. 3703507 describes a process for preparing the 5'-phosphate ester of a nucleoside, in which the corresponding nucleoside is reacted with phosphorus oxychloride (POC'3) in acetic acid in the presence of pyridine. United States
Patent Specification No. 3,413,282 discloses a process in which the corresponding nucleoside is reacted with POCI3 or diphosphoryl chloride (P203CI4) in the presence of a
trialkyl phosphate solvent, the reaction product is hydrolyzed and neutralized, and the desired nucleotide product is isolated by adsorption and elution techniques using activated carbon or ion exchange resin. These known processes undesirably involve time-consuming manipulations and processing steps; they also use costlv adsorbing media and elution solvents.
One aspect of the present invention provides a process for the production of the ester product 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, which comprises reacting 9-(ss-D- arabinofuranosyl) adenine with a phosphorylating agent to form a 5'-monophosphorylated intermediate product in the presence of a tnalkyl phosphate solvent, subjecting the reaction mixture to aqueous hydrolysis, adjusting the pH of the aqueous hydrolysis mixture upward sufficiently to cause separation into aqueous and non-aqueous liquid phases, removing the trialkyl phosphate solvent from the aqueous mixture, maintaining the residual aqueous mixture at a pH at which the ester product is insoluble to cause said ester product to precipitate as a solid phase from the aqueous mixture, and isolating said product. The process of the present invention advantageously provides good yields of the desired product in crystalline form. The process also provides a favorable ratio of required volume to product yield thereby permitting increased batch sizes; the product work-up is simple, and labour and material needs are minimized.
The process of the invention is subject to considerable variation. The starting material, 9- (ss-D-arabinofuranosyl)-adenine can be used either as the monohydrate or in the anhydrous form, the anhydrous nucleoside being preferred. The phosphorylating agent employed is any suitable agent; it may, for instance, contain halogen as is the case with a phosphorous oxyhalide, in particular POCIX, POBrR and P2OXCI4. The phosphorylating agent is preferably used in a ratio of about 1 to 5 moles, and more preferably 1.15 to 2 moles, for each mole of 9-(ss-D-arabinofuranosyl) adenine. Phosphorus oxychloride is a preferred phosphorylating agent. The trialkyl phosphate solvent used is preferably an ester of phosphoric acid with a C, to C4 aliphatic alcool, such as trimethyl phosphate or triethyl phosphate. Triethyl phosphate is a preferred solvent. The molar ratio of trialkyl phosphate solvent to nucleoside in the process is preferably at least 5 to 1. A ratio of approximately 15 to 1 is more preferred as it gives better results. The phosphorylation is ordinarily carried out
at a temperature in the range from-30 to 50 C. The preferred range is in the range-10 to +10 C, at which the reaction is usually complete in about 2 to 5 hours. At-20 C. the
reaction time is usually from 6 to 10 hours and at 30 C. usually from 10 to 30 minutes. If the
phosphorylating agent contains halogen, e. g. chlorine, there may be produced a
phosphorodihalidate or trichlorodiphosphate intermediate which, following the reaction, is hydrolyzed to provide the ester product. This can be done by combining ice and/or water
with the reaction mixture. The pH of the resulting aqueous mixture is according to the
present invention adjusted upwardly by addition of base such as sodium hydroxide solution
in sufficient amount to cause separation into an aqueous liquid phase and a non-aqueous
liquid phase, preferably to a value in the pH range from 1 to 2.5. The resulting mixture,
which forms the two liquid phases, is preferably extracted with an inert water-immiscible solvent such as dichloromethane or diethy ether to remove the trialkyl phosphate. Since
the desired product, 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, is water-soluble at
relatively low pH and at relatively high pH, the extracted aqueous phase is maintained
according to the invention, if necessary after further adjustment, at a pH at which the
product is insoluble (depending on conditions suitably in the pH range from 1.3 to 2.5) and
the mixture is held, preferably in the cold and with seeding, to cause the desired ester
product to precipitate as a solid phase from the aqueous mixture. The product, obtained in
pure crystalline form, is isolated in free acid form by conventional means such as filtration
or centrifugation. The product can be recrystallized, if desired, or converted to salt form in
solution by conventional means, for example, by appropriate adjustment of the pH. In an
optional procedure, which constitutes a further aspect of the present invention, instead of hydrolyzing the reaction mixture directly in water as described, one can hydrolyze the
monophosphorylated intermediate product, e. g. as a phosphorodihalidate or trichlor
odiphosphate, obtained as a precipitate by adding the reaction mixture to a non-aqueous
liquid (such as dichloromethane or diethyl ether) in which the intermediate is insoluble.
Thus the further aspect of the present invention provides a process for the production of
the ester product 9- (p-D-arabinofuranosy !) adenine, 5'-phosphate, which comprises react- ing 9-(ss-D-arabinofuranosyl) adenine with a phosphorylating agent to form a 5'- monophosphorylated intermediate product in the presence of a trialkyl phosphate solvent,
treating the reaction mixture with a non-aqueous diluent in which the intermediate product.
is insoluble so as to cause the intermediate product to separate as a solid, isolating the solid
and subjecting it to aqueous hydrolysis, maintaining the aqueous hydrolysis mixture at a pH
at which the ester product is insoluble so as to cause the ester product to precipitate from
the aqueous mixture and isolating the ester product. The conditions employed in this aspect
may generally be like those in the first-mentioned aspect.
The product, 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate is useful as a
pharmacological agent, especially as an antiviral agent, being active against Herpes simplex
virus, as described in the above-mentioned U. S. Patent No. 3,703,507.
The present invention is illustrated by the following examples.
Example 1 A stirred mixture of 10.69 g. (0.04 mole) of anhydrous 9-(ss-D-arabinofuranosyl) adenine in 100 ml. (0.586 mole) of triethyl phosphate was cooled to 0-2 C. in an ice bath. To this
stirred slurry was then added 7.05 g. (0. 046 mole) of phosphorus oxychloride dropwise during a two hour period while maintaining ice bath cooling. The mixture was then stirred
cold for another hour to give a clear to slightly hazy solution which was poured onto 70 g. of
ice. The reaction flask was rinsed with 10 ml. of ice water and this was added to the
hydrolysis mixture which was then stirred in an ice bath for about 15 minutes. The mixture
was stirred with cooling while the pH was adjusted from 0.6 to 2 using 50% sodium
hydroxide solution. A second liquid phase separated and the temperature rose to about 10 C. during this step. The mixture was stirred for another 15 minutes while the pH was held at
2 by the addition of more base.
The mixture was then transferred to a separatory funnel and extracted with 100 ml. of dichloromethane. The lower phase (non-aqueous, about 200 ml.) was removed and the
aqueous layer was again extracted using 50 ml. of dichloromethane. The layers were again
separated and the upper (aqueous) phase was readjusted to pH 2 using a few drops of base.
This solution was seeded with a few crystals of 9-(ss-D-arabinofuranosyl) adenine, 5'
phosphate, and stirred at room temperature until precipitation was well underway (about
10 minutes). Stirring was then stopped and the mixture was allowed to stand in the cold
overnight. The resulting white crystalline mass was broken up by stirring and again allowed
to stand overnight in the cold. The mixture was then filtered with suction, and the crystalline product, 9-(ss-D-arabinofuranosvl) adenine, 5'-phosphate, was washed succes
sively with ice water (22 ml.), cold 50% aqueous ethanol (35 ml.), and cold adsolute ethanol (25 ml.). After drying at 40 C. izl vacuo for 16 hours the product weighed 10.59 g. (76.2% of theory) and analyzed as follows:
Ion Exchange Column Chromatography-UV Assay :
Fraction I (unreacted nucleoside + adenine): 1.57%
Fraction II (desired 5'-phosphate product): 91.2%
Fraction III (diphosphates): 1.98%
K. Fisher Water 5. 62%
Total = 100. 37%
The corrected yield of 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate was therefore 69. 5% of theory.
The-product analysis is carried out by the following procedure which is typical:
Ion Exchange Column Chromatography-UV Assay A chromatographic column (9 mm. x 15 cm.) is packed with 0.5 g. of anion exchange resin (QAE-Sephadex A-25, CI') which has been suspended in distilled water overnight.
The word"Sephadex"is a registered Trade Mark. Approximately 20 mg. of sample is accurately weighed and dissolved in 1.0 ml. of 0. 1N NaOH and this solution is transferred. to the column. The column is then eluted with water until a total of 25 ml. has been collected in a volumetric flask. This fraction contains unreacted 9-(ss-D- arabinofuranosyl) adenine and adenine. The column is then eluted with 0. 1M phosphate buffer (pH 7.0) until 50 ml. has been collected. This second fraction contains the desired 5'-phosphate product. A third fraction containing diphosphate esters is obtained by eluting with 0.4M phosphate buffer (pH 7.0) until a total of 50 ml. has been collected.
The UV spectrum of each fraction is run at 320-220 nm. (Fractions 1 and 3 without dilution and fraction 2 after a 20-fold dilution). From the adsorption at 260 nm. (A X260), the contents of each fraction are calculated as follows:
A
mg. of component = 260 x 10 x V x D
a (lac, 1 cm.) k260 where V = volume (ml.) of each fraction
D = dilution a (1%, 1 cm.) k260 = 569 for 9- ( (3-D-arabinofuranosyl)- adenine (Fraction I) = 437 for the 5'-phosphate product
(Fraction II) = 361 for the diphosphates
(Fraction III)
From the amount of each component, the percent of each is then calculated.
Example 2
To 100 ml. of stirred, cold (2 C.) triethyl phosphate was added 9.20 g. (0. 06 mole) of phosphorus oxychloride within a two minute period. To this stirred solution was then added 10.69 g. (0.04 mole) of anhydrous 9-(ss-D-arabinofuranosyl) adenine in one portion with a resultant reaction temperature rise to about 4 C. The mixture was stirred in the ice bath for 2 hours 10 minutes, producing a clear solution about 1 hour 50 minutes after the addition.
The reaction solution was then poured into 800 ml. of cold diethyl ether and stirred for one hour in an ice bath. This white suspension was filtered in the cold and the hygroscopic solid was washed twice with 100-ml. portions of cold solvent, then dissolved in 80 ml. of water.
After separating an ether layer, the aqueous solution was adjusted to pH 2 using 50% sodium hydroxide solution, then seeded with pure 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, and placed in the refrigerator to cool for two days with occasional stirring.
The precipitate was then filtered, washed in turn with 35 ml. of cold 50% ethanol and 25 ml. of cold absolute ethanol, and finally, dried in vacuo at 40 C. to give 8.88 g. (63.9% of theory) of 9-(ss-D-arabinofuranosyl)-adenine, 5'-phosphate, assaying as follows:
Ion Exchange Column Chromatography-UV assay :
Fraction I (unreacted nucleoside + adenine): 0.38%
Fraction II (desired 5'-phosphate product): 92.8%
Fraction III (diphosphates): 4. 03% The corrected yield of 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, was therefore 59. 3% of theory.
Example 3
To 100 ml. of triethyl phosphate was added 10.69 g. (0.04 mole) of anhydrous 9- (ss-D-arabinofuranosyl) adenine in one portion with stirring. This mixture was cooled in an ice bath to 2 C. and 9.20 g. (0.06 mole) of phosphorus oxychloride was then added during a three-minute period, the temperature rising to aout 4 C. The reaction mixture was
stirred in the cold for 2 hours 30 minutes, after which the clear solution was poured into 80
g. of ice. This mixture was stirred in an ice bath to maintain a temperature below 10 C. while the pH was adjusted to 2 using 50% sodium hydroxide solution. The resulting turbid
mixture was extracted twice using 100-ml. and 50-ml. portions of dichloromethane and the
aqueous layer was again adjusted to pH 2 using additional caustic. After seeding, this
solution was placed in the refrigerator overnight to give a dense white precipitate. This was
stirred with a glass rod and again allowed to stand overnight in the cold. The white product was filtered and washed using 22 ml. of ice water, 35 ml. of cold 50% ethanol and 25-ml. of
cold absolute ethanol. After drying in vacuo at 40 C., 9.60 g. (69.1% of theory) of the
product, 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, was obtained which assayed as
follows :
Ion Exchange Column Chromatography-UV assay :
Fraction I (unreacted nucleoside + adenine): 0.17%
Fraction 11 (desired 5'-phosphate product): 89.9%
Fraction III (diphosphates): 4.54%
The corrected yield of 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate was therefore 62.1%
of theory.
Example 4
To an ice bath-cooled solution of 0.72 ml. (0.04 mole) of water in 100 ml. of triethyI phosphate was slowly added 12.27 g. (0.08 mole) of phosphorus oxychloride at 0-5 C.
Anhydrous 9-(ss-D-arabinofuranosyl) adenine (10.69 g., 0.04 mole) was then added in one
portion with stirring to give an immediate temperature rise from 1 to 9 C. The reaction
mixture was clear in 30 minutes and after 2 hours 30 minutes it was poured onto 100 g. of ice
and the pH was adjusted to 2 using 50% sodium hydroxide solution. After extracting twice
using 200-ml. and 100-ml. portion of diethyl ether, the pH was again adjusted using
additional base. The aqueous solution was then seeded with crystals of 9-(ss-D- arabinofuranosyl) adenine, 5'-phosphate, and cooled in the refrigerator to precipitate the
product, 9-(6-D-arabinofuranosy)) adenine, 5'-phosphate, as described in previous exam
ples. After filtering, washing, and drying, the white product weighed 10.12 g. (72.9% of
theory) and assayed as follows:
Ion Exchange Column Chromatography-UV Assay :
Fraction I (unreacted nucleoside + adenine): 4.08%
Fraction II (desired 5'-phosphate product): 81.1%
Fraction III (diphosphates): 1.51%
The corrected yield of 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, was 59.1%.
Example S To a stirred slurry of 10.69 g. (0.04 mole) of 9-(ss-D-arabinofuranosyl) adeníne in 100 ml. of triethylphosphate cooled to 2 C. in an ice bath was added during a 2-hour period 11.58 g.
(0.046 mole) of diphosphoryl chloride (P203Cl4). The white reaction mixture was stirred in the cold for an additional hour, becoming a clear solution during this time. This solution was then poured onto 80 g. of ice and 50% sodium hydroxide solution was added to this stirred, ice bath-cooled mixture to adjust the pH to 2. After extracting with dichloromethane, readjusting the pH and seeding, the aqueous solution was cooled. The product which separated as a white crystalline solid, 9-(ss-D-arabinofuranosyl) adenine, 5'phosphate, was collected by filtration and washed and dried, as described in previous examples to give 8.26 g. (59.5% of theory) which assayed as follows:
Ion Exchange Column Chromatography-UV Assay :
Fraction I (unreacted nucleoside + adenine) :. 0. 24%
Fraction 11 (desired 5'-phosphate product): 94.3%
Fraction III (diphosphates): 2.0% R. Fisher Water : 5.77%
Total = 102. 3%
The corrected yield of 9- (P-D-arabinofuranosyl) adenine, 5'-phosphate was therefore 56.1% of theory.
Claims (17)
1. A process for the production of the ester product 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, which comprises reacting 9-(ss-D-arabinofuranosyl) adenine with a phos phorylating agent to form a 5'-monophosphorylated intermediate product in the presence of a trialkyl phosphate solvent, subjecting the reaction mixture to aqueous hydrolysis, adjusting the pH of the aqueous hydrolysis mixture upwards sufficiently to cause separation into aqueous and non-aqueous liquid phases, removing the trialkyl phosphate solvent from the aqueous mixture, maintaining the residual aqueous mixture at a pH at which the ester product is insoluble so as to cause the ester product to precipitate from the residual aqueous mixture, and isolating the ester product.
2. A process for the production of the ester product 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, which comprises reacting 9-(ss-D-arabinofuranosyl) adenine with a phosphorylating agent to form a 5'-monophosphorylated intermediate product in the presence of a trialkyl phosphate solvent, treating the reaction mixture with a non-aqueous diluent in which the intermediate product is insoluble so as to cause the intermediate product to separate as a solid, isolating the solid and subjecting it to aqueous hydrolysis, maintaining the aqueous hydrolysis mixture at a pH at which the ester product is insoluble so as to cause the ester product to precipitate from the aqueous mixture, and isolating the ester product.
3. A process according to Claim 1, in which the phosphorylating agent is used in a ratio of 1.15 to 2 moles for each mole of 9-(ss-D-arabinofuranosyl) adenine.
4. A process according to Claim 1 or 3, in which the phosphorylating agent is phosphorus oxychloride.
5. A process according to Claim 1,3 or 4, in which the trialkyl phosphate solvent is triethyl phosphate.
6. A process according to any one of Claims 1 and 3 to 5, in which the molar ratio of trialkyl phosphate solvent to 9-(ss-D-arabinofuranosyl) adenine is approximately 15 to 1.
7. A process according to any one of Claims 1 and 3 to 6, in which the phosphorylation is carried out at a temperature in the range from-10 to +10 C.
8. A process according to any one of Claims 1 and 3 to-7, in which the aqueous hydrolysis mixture is adjusted to a pH in the range from 1 to 2.5.
9. A process according to any one of Claims 1 and 3 to 8, in which the residual aqueous mixture is maintained at a pH in the range from 1.3 to 2.5.
10. A process according to Claim 2, in which the phosphorylating agent is used in a ratio of 1.15 to 2 moles for each mole of 9-(ss-D-arabinofuranosyl) adenine.
11. A process according to Claim 2 or 1U, in which the phosphorylating agent is phosphorus oxychloride.
12. A process according to Claim 2,10 or 11, in which the trialkyl phosphate solvent is triethyl phosphate.
13. A process according to any one of Claims 2 and 10 to 12, in whico the molar ratio of trialkyl phosphate to 9-(ss-D-arabinofuranosyl) adenine is approximately 15 to 1.
14. A process according to any one of Claims 2 and 10 to 13, in which the phosphorylation is carried out at a temperature in the range from-10 to +10 C.
15. A process according to any one of Claims 2 and 10 to 14, in which the aqueous hydrolysis mixture is maintained at a pH in the range from 1.3 to 2.5.
16. A process for the production of the ester product 9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, substantially as described in any one of the foregoing Examples.
17.9-(ss-D-arabinofuranosyl) adenine, 5'-phosphate, whenever produced by the process claimed in any one of the preceding claims.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73842576A | 1976-11-03 | 1976-11-03 | |
US05/831,703 US4123609A (en) | 1976-11-03 | 1977-09-12 | Process for the production of 9-(β-D-arabinofuranosyl)adenine, 5'-phosphate |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1559456A true GB1559456A (en) | 1980-01-16 |
Family
ID=27113366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB4564777A Expired GB1559456A (en) | 1976-11-03 | 1977-11-02 | Process for the production of 9-d-arabinofuranosyl-adenine5-phosphate |
Country Status (12)
Country | Link |
---|---|
JP (1) | JPS5356691A (en) |
AT (1) | AT358187B (en) |
CA (2) | CA1077030A (en) |
CH (1) | CH626377A5 (en) |
DE (1) | DE2749056A1 (en) |
DK (1) | DK151263C (en) |
ES (1) | ES463768A1 (en) |
FR (1) | FR2370057A1 (en) |
GB (1) | GB1559456A (en) |
HK (1) | HK3884A (en) |
NL (1) | NL191060C (en) |
SE (1) | SE442404B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1383572A (en) * | 1964-02-28 | 1964-12-24 | Necchi Spa | Improvements in automatic shut-off devices for sewing machines |
DE1645896C3 (en) * | 1965-03-17 | 1975-01-02 | Ajinomoto Co., Inc., Tokio | Process for the preparation of 5'-ribonucleotides and S'-deoxyribonucleotides |
BE756704A (en) * | 1969-09-26 | 1971-03-01 | Parke Davis & Co | PROCESS FOR THE PRODUCTION OF 5'-PHOSPHATE OF 9- (BETA-D- ARABINOFURANOSYL) ADENINE AND ITS SALTS |
-
1977
- 1977-11-02 FR FR7732871A patent/FR2370057A1/en active Granted
- 1977-11-02 CA CA290,047A patent/CA1077030A/en not_active Expired
- 1977-11-02 DE DE19772749056 patent/DE2749056A1/en active Granted
- 1977-11-02 DK DK487177A patent/DK151263C/en not_active IP Right Cessation
- 1977-11-02 NL NL7712102A patent/NL191060C/en not_active IP Right Cessation
- 1977-11-02 JP JP13216277A patent/JPS5356691A/en active Pending
- 1977-11-02 SE SE7712368A patent/SE442404B/en not_active IP Right Cessation
- 1977-11-02 GB GB4564777A patent/GB1559456A/en not_active Expired
- 1977-11-02 AT AT779577A patent/AT358187B/en not_active IP Right Cessation
- 1977-11-02 CH CH1335777A patent/CH626377A5/en not_active IP Right Cessation
- 1977-11-02 ES ES463768A patent/ES463768A1/en not_active Expired
-
1979
- 1979-12-18 CA CA342,182A patent/CA1088927A/en not_active Expired
-
1984
- 1984-01-12 HK HK3884A patent/HK3884A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE2749056A1 (en) | 1978-05-18 |
CA1088927A (en) | 1980-11-04 |
DE2749056C2 (en) | 1987-07-16 |
NL191060C (en) | 1995-01-02 |
CH626377A5 (en) | 1981-11-13 |
AT358187B (en) | 1980-08-25 |
ATA779577A (en) | 1980-01-15 |
NL7712102A (en) | 1978-05-08 |
DK151263C (en) | 1988-05-16 |
HK3884A (en) | 1984-01-20 |
FR2370057B1 (en) | 1980-06-13 |
NL191060B (en) | 1994-08-01 |
ES463768A1 (en) | 1978-06-01 |
FR2370057A1 (en) | 1978-06-02 |
SE7712368L (en) | 1978-05-04 |
DK151263B (en) | 1987-11-16 |
JPS5356691A (en) | 1978-05-23 |
SE442404B (en) | 1985-12-23 |
DK487177A (en) | 1978-05-04 |
CA1077030A (en) | 1980-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4123609A (en) | Process for the production of 9-(β-D-arabinofuranosyl)adenine, 5'-phosphate | |
Wechter | Nucleic acids. I. The synthesis of nucleotides and dinucleoside phosphates containing ara-cytidine | |
US3448098A (en) | Production of guanylic acid | |
US4590269A (en) | Process for preparing the cyclic phosphate ester of substituted 9-(1,3-dihydroxy-2-propoxymethyl)purines | |
US5420302A (en) | Preparation of calcium L-ascorbate 2-phosphate | |
Young et al. | Total synthesis of the four stereoisomers of dihexadecanoyl phosphatidylinositol and the substrate stereospecificity of human erythrocyte membrane phosphatidylinositol 4-kinase | |
GB1559456A (en) | Process for the production of 9-d-arabinofuranosyl-adenine5-phosphate | |
EP0432297A1 (en) | A method for the preparation of the sodium salt of O-formyl cefamandole | |
EP0217765B1 (en) | Process for the preparation of l-alpha-glycerylphosphorylcholine, l-alpha-glycerylphosphorylethanolamine from crude and/or deoleated lecithins | |
US3658848A (en) | Method for production of ascorbic acid-3-phosphate | |
US3290285A (en) | Method of production of 5'-guanylic acid | |
EP0138683A2 (en) | Purine derivatives, their application in anti-viral compositions | |
HU210285B (en) | Process for preparing l-alpha-glyceryl phosphoryl-d-myoinositol and its salts | |
US3803125A (en) | Process for making nucleoside diphosphate compounds | |
US2700038A (en) | Dibasic salts of adenosine triphosphate and method of preparation | |
EP0487719B1 (en) | Process for the preparation of 9-beta-d-arabinofuranosyl-2-fluoroadenine 5'-phosphate | |
US3393253A (en) | Ureidophosphonates and preparation thereof | |
US2795580A (en) | Synthesis of nucleoside polyphosphates | |
SU862828A3 (en) | Method of preparing 9-(2-oxyethoxymethyl) guaninephosphates | |
HU198947B (en) | Process for producing purin-9-yl-alkoxy-methyl-phosphonic acid derivatives | |
US2152662A (en) | Method for preparing ribose | |
US7351830B2 (en) | Pancratistatin cyclic phosphate prodrugs and phenpanstatin cyclic phosphate prodrugs | |
EP1464708A1 (en) | A process for the preparation of fludarabine phosphate from 2-fluoroadenine | |
Andrei et al. | Stereoselective preparation of (Rp)-8-hetaryladenosine-3′, 5′-cyclic phosphorothioic acids | |
FI115836B (en) | A method for preparing asymmetric phosphoric acid diesters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
732 | Registration of transactions, instruments or events in the register (sect. 32/1977) | ||
PE20 | Patent expired after termination of 20 years |
Effective date: 19971101 |